Aug 14 (Reuters) - Eli Lilly ( LLY ) has sent

cease-and-desist letters to US healthcare providers in recent

days demanding they stop promoting copycat weight-loss drugs as

the supply of the company's drug Zepbound improves, Bloomberg

News reported on Wednesday.

Lilly now considers the brand name drug to be available and

thinks compounded drugs made at state-licensed facilities should

not be sold anymore, the report added, citing a spokesperson.

The company did not immediately respond to a Reuters request

for comment.